FDA approves first CRISPR therapy-here's how it works against sickle cell
The FDA has approved two gene therapies for the treatment of sickle cell disease, one of which is the first CRISPR/Cas9-based treatment to be approved in the US.
Sickle cell disease affects around 100,000 people in the US and can lead to anemia, organ damage, and early death.